PMI CLASS ACTION: Picard Medical, Inc. Investors with Significant Losses Should Contact Robbins LLP for Information About Recovering Their Losses

Core Viewpoint - A class action lawsuit has been filed against Picard Medical, Inc. (NYSE: PMI) on behalf of investors who acquired its securities between September 2, 2025, and October 31, 2025, due to allegations of a fraudulent stock promotion scheme [1] Allegations - The lawsuit alleges that Picard Medical failed to disclose involvement in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [1] - It is claimed that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [1] - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [1] Stock Price Impact - On October 24, 2025, Picard Medical's stock price plummeted by 70%, dropping to $3.99 per share, and has since continued to decline to approximately $2.00 per share [1] Shareholder Actions - Shareholders may be eligible to participate in the class action and those wishing to serve as lead plaintiff must file their papers with the court by April 3, 2026 [1] - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [1] Legal Representation - Robbins LLP, a firm specializing in shareholder rights litigation, is representing the class action on a contingency fee basis, meaning shareholders pay no fees or expenses unless a recovery is achieved [1]